Evidence map›Paper›PMID 32625009›Full record

ArticleEngineering in life sciences2019

Specific N-demethylation of verapamil by cytochrome P450 from

Chen Shen, Hanqing Liu, Wenling Dai, Xiufeng Liu, Jihua Liu, Boyang Yu

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Engineering in life sciences, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.2field-weighted citation impact, top 43% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 5 citations in OpenAlex.

  1. International journal of molecular sciences · 2025
    Article
  2. Molecules (Basel, Switzerland) · 2022
    Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Chen ShenJiangsu Key Laboratory of TCM Evaluation and Translational Research School of Traditional Chinese Pharmacy China Pharmaceutical University Nanjing Jiangsu P. R. China.
Hanqing LiuJiangsu Key Laboratory of TCM Evaluation and Translational Research School of Traditional Chinese Pharmacy China Pharmaceutical University Nanjing Jiangsu P. R. China.
Wenling DaiJiangsu Key Laboratory of TCM Evaluation and Translational Research School of Traditional Chinese Pharmacy China Pharmaceutical University Nanjing Jiangsu P. R. China.
Xiufeng LiuJiangsu Key Laboratory of TCM Evaluation and Translational Research School of Traditional Chinese Pharmacy China Pharmaceutical University Nanjing Jiangsu P. R. China.
Jihua LiuJiangsu Key Laboratory of TCM Evaluation and Translational Research School of Traditional Chinese Pharmacy China Pharmaceutical University Nanjing Jiangsu P. R. China.
Boyang YuJiangsu Key Laboratory of TCM Evaluation and Translational Research School of Traditional Chinese Pharmacy China Pharmaceutical University Nanjing Jiangsu P. R. China.
China Pharmaceutical University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Norverapamil, the N-demethylated derivative of verapamil, is a novel promising leading compound for attenuating multidrug resistance with less side effects compared with verapamil. However, the efficient synthetic method for norverapamil is absent. In this study, an innovative biotechnological method based on enzymatic catalysis was presented for the high-efficient production of norverapamil. CYP105D1, a cytochrome P450 from

Indexed as

biocatalysiscytochrome P450N‐demethylationnorverapamilverapamil

Identifiers

PMID32625009
PMCPMC6999465
OpenAlexW2912295420

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.